Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-03T08:10:52.119Z Has data issue: false hasContentIssue false
  • English
  • Français

GLP-1 receptor agonists have a sustained stimulatory effect on corticosterone release after chronic treatment

Published online by Cambridge University Press:  03 December 2014

Maarja Krass ,
Annika Volke ,
Kertu Rünkorg ,
Gregers Wegener ,
Sten Lund ,
Anders Abildgaard Open the ORCID record for Anders Abildgaard [Opens in a new window] ,
Eero Vasar  and
Vallo Volke
Maarja Krass
Affiliation:
Department of Physiology, University of Tartu, Tartu, Estonia Center for Translational Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia
Annika Volke
Affiliation:
Department of Dermatology; University of Tartu, Tartu, Estonia
Kertu Rünkorg
Affiliation:
Department of Physiology, University of Tartu, Tartu, Estonia Center for Translational Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia
Gregers Wegener
Affiliation:
Translational Neuropsychiatry Unit, Aarhus University, Risskov, Denmark Centre of Excellence for Pharmaceutical Sciences, School of Pharmacy (Pharmacology), North-West University, Potchefstroom, South Africa
Sten Lund
Affiliation:
Medical Department MEA (Endocrinology), Aarhus University Hospital, Aarhus C, Denmark
Anders Abildgaard
Affiliation:
Translational Neuropsychiatry Unit, Aarhus University, Risskov, Denmark
Eero Vasar
Affiliation:
Department of Physiology, University of Tartu, Tartu, Estonia Center for Translational Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia
Vallo Volke*
Affiliation:
Department of Physiology, University of Tartu, Tartu, Estonia Center for Translational Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia
*
Prof. Vallo Volke, Department of Physiology, Institute of Biomedicine and Translational Medicine University of Tartu, 19 Ravila Street, 50411 Tartu, Estonia. Tel. +372 7 374338; Fax: +372 7 374332;E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Glucagon-like peptide 1 (GLP-1) receptor agonists are a new group of antidiabetic medications quickly gaining popularity. We aimed to examine behavioural and neuroendocrine changes following chronic treatment with GLP-1 receptor agonists in animal models.

Methods

The effects of chronic treatment with GLP-1 receptor agonists were determined on behavioural parameters [anxiety level in the light–dark compartment test, the motor activity in automated activity cages, immobility in the forced swimming test (FST)] and on corticosterone release in mice. The possible antidepressant effect of chronic liraglutide treatment was also studied in Flinders Sensitive Line (FSL) rats, a genetic model of depression.

Results

Two weeks of treatment with exenatide (10 µg /kg twice daily) or liraglutide (1200 µg/kg once daily) did not affect the anxiety level in a light–dark compartment test nor induce an antidepressant-like effect in the FST in mice. Moreover, chronic treatment with liraglutide had no effect on depression-related behaviour in FSL rats. Interestingly, hypolocomotion induced by the drugs in mice disappeared after chronic dosing. Both of the GLP-1 receptor agonists induced robust increases in corticosterone levels in mice under basal conditions as well as in the case of combination with swimming stress. Remarkably, exenatide was as potent a stimulator of corticosterone release after 2 weeks as after acute administration.

Conclusions

The increases in corticosterone release seen after acute exenatide or liraglutide treatment do not abate after 2 weeks of treatment demonstrating that tolerance does not develop towards this particular effect of GLP-1 agonists.

Keywords

corticosteroneexenatideliraglutideneuroendocrinologystress
Type
Original Articles
Information
Acta Neuropsychiatrica , Volume 27 , Issue 1 , February 2015 , pp. 25 - 32
Check for updates
Copyright
© Scandinavian College of Neuropsychopharmacology 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Drucker, DJ, Nauck, MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696–1705.Google Scholar
2.Ussher, JR, Drucker, DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33:187–215.CrossRefGoogle ScholarPubMed
3.Salcedo, I, Tweedie, D, Li, Y, Greig, NH. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol 2012;166:1586–1599.Google Scholar
4.Lockie, SH. Glucagon-like peptide-1 receptor in the brain: role in neuroendocrine control of energy metabolism and treatment target for obesity. J Neuroendocr 2013;25:597–604.CrossRefGoogle ScholarPubMed
5.McKay, NJ, Daniels, D. Glucagon-like peptide-1 receptor agonist administration suppresses both water and saline intake in rats. J Neuroendocr 2013;25:929–938.CrossRefGoogle ScholarPubMed
6.Kanoski, SE, Rupprecht, LE, Fortin, SM, De Jonghe, BC, Hayes, MR. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 2012;62:1916–1927.Google Scholar
7.Punjabi, M, Arnold, M, Rüttimann, Eet al. Circulating glucagon-like peptide-1 (GLP-1) inhibits eating in male rats by acting in the hindbrain and without inducing avoidance. Endocrinology 2014;155:1690–1699.Google Scholar
8.Labouesse, MA, Stadlbauer, U, Weber, E, Arnold, M, Langhans, W, Pacheco-Lopez, G. Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4. J Neuroendocr 2012;24:1505–1516.Google Scholar
9.During, MJ, Cao, L, Zuzga, DSet al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003;9:1173–1179.Google Scholar
10.Egecioglu, E, Steensland, P, Fredriksson, I, Feltmann, K, Engel, JA, Jerlhag, E. The glucagon-like peptide 1 analogue exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 2013;38:1259–1270.Google Scholar
11.Isacson, R, Nielsen, E, Dannaeus, Ket al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur J Pharmacol 2011;650:249–255.Google Scholar
12.Moller, C, Sommer, W, Thorsell, A, Rimondini, R, Heilig, M. Anxiogenic-like action of centrally administered glucagon-like peptide-1 in a punished drinking test. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:119–122.Google Scholar
13.Porsolt, RD, Bertin, A, Jalfre, M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327–336.Google ScholarPubMed
14.Krass, M, Runkorg, K, Vasar, E, Volke, V. Acute administration of GLP-1 receptor agonists induces hypolocomotion but not anxiety in mice. Acta Neuropsychiatr 2012;24:296–300.Google Scholar
15.Gil-Lozano, M, Perez-Tilve, D, varez-Crespo, Met al. GLP-1(7-36)-amide and exendin-4 stimulate the HPA axis in rodents and humans. Endocrinology 2010;151:2629–2640.Google Scholar
16.Malendowicz, LK, Neri, G, Nussdorfer, GG, Nowak, KW, Zyterska, A, Ziolkowska, A. Prolonged exendin-4 administration stimulates pituitary–adrenocortical axis of normal and streptozotocin-induced diabetic rats. Int J Mol Med 2003;12:593–596.Google ScholarPubMed
17.MacLusky, NJ, Cook, S, Scrocchi, Let al. Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology 2000;141:752–762.Google Scholar
18.Gil-Lozano, M, Romani-Perez, M, Outeirino-Iglesias, Vet al. Effects of prolonged exendin-4 administration on hypothalamic–pituitary–adrenal axis activity and water balance. Am J Physiol Endocrinol Metab 2013;304:E1105–E1117.Google Scholar
19.Overstreet, DH, Wegener, G. The flinders sensitive line rat model of depression – 25 years and still producing. Pharmacol Rev 2013;65:143–155.Google Scholar
20.Crawley, J, Goodwin, FK. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 1980;13:167–170.CrossRefGoogle ScholarPubMed
21.Abildgaard, A, Solskov, L, Volke, V, Harvey, BH, Lund, S, Wegener, G. A high-fat diet exacerbates depressive-like behavior in the Flinders Sensitive Line (FSL) rat, a genetic model of depression. Psychoneuroendocrinology 2011;36:623–633.Google Scholar
22.Detke, MJ, Rickels, M, Lucki, I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacol 1995;121:66–72.CrossRefGoogle ScholarPubMed
23.Krass, M, Wegener, G, Vasar, E, Volke, V. Antidepressant-like effect of agmatine is not mediated by serotonin. Behav Brain Res 2008;188:324–328.Google Scholar
24.Kinzig, KP, D’Alessio, DA, Herman, JPet al. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci 2003;23:6163–6170.Google Scholar
25.Ali, S, Stone, MA, Peters, JL, Davies, MJ, Khunti, K. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2006;23:1165–1173.CrossRefGoogle ScholarPubMed
26.Jelsing, J, Vrang, N, Hansen, G, Raun, K, Tang-Christensen, M, Knudsen, LB. Liraglutide: short-lived effect on gastric emptying – long lasting effects on body weight. Diabetes Obes Metab 2012;14:531–538.Google Scholar